As a further matter, genetically engineered bacteria represent a promising approach to modulate the gut microbiota, being designed to express therapeutic agents that enhance satiety and boost sensitivity to leptin, while also serving as a delivery system for therapeutic molecules targeting obesity-related conditions that are otherwise challenging to administer [158]. Here, LEP is linked to obesity due to melanocortin 4 receptor deficiency.